Vaxart, Inc., a biotechnology company based in South San Francisco, USA, has recently garnered attention in the healthcare sector with its innovative approach to vaccine development. Specializing in oral flu vaccines, Vaxart’s technology stimulates the immune system through the gut, eliciting both systemic and mucosal immune responses. This unique method positions the company at the forefront of vaccine innovation, serving a global customer base via its online platform at www.vaxart.com .
In a significant development, Vaxart announced positive data on January 15, 2026, regarding its oral bivalent norovirus vaccine, specifically targeting lactating women and infants. This announcement, disseminated through OTCMarkets, underscores the company’s commitment to addressing critical public health needs through novel vaccine delivery methods. The stock, trading on the Nasdaq stock exchange, closed at $0.56 on the same day, reflecting a position near the lower end of its 52-week trading range.
Over the past year, Vaxart’s stock has experienced fluctuations, with a low of $0.26 on July 8, 2025, and a peak of $0.84 on January 11, 2026. As of February 12, 2026, the closing price stood at $0.57. These movements highlight the volatility and investor interest in the company’s potential to revolutionize vaccine delivery.
Financially, Vaxart presents a complex picture. The company’s price-to-earnings (P/E) ratio is currently at -2.52, indicative of earnings deficits. This negative P/E ratio is not uncommon in biotech firms, particularly those in the development phase of innovative products. Additionally, the price-to-book (P/B) ratio is 5.44, suggesting that the market values the company at more than five times its book value. This valuation reflects investor confidence in Vaxart’s long-term potential despite current financial metrics.
With a market capitalization of approximately $135.83 million, Vaxart’s financial standing is modest yet significant within the biotechnology sector. The company’s focus on developing oral vaccines, a field with substantial unmet medical needs, positions it as a potentially transformative player in global healthcare.
As Vaxart continues to advance its vaccine technologies, the healthcare sector will closely monitor its progress. The recent positive data on the norovirus vaccine for lactating women and infants is a promising step forward, potentially paving the way for broader applications and market acceptance. Investors and industry observers alike will be keen to see how Vaxart navigates the challenges and opportunities ahead, leveraging its innovative platform to address pressing public health issues.
